The current review concentrates on the latest breakthroughs of triazole-pyrimidines as target-based anticancer representatives, including works posted between 2007 and the current (2007-2022). The structure-activity interactions (SARs) and several paths will also be evaluated to reveal the development of more efficient and biotargeted anticancer…[Read more]